Chronic Stress Weakens Connectivity in the Prefrontal Cortex: Architectural and Molecular Changes

Elizabeth Woo1,2, Lauren H. Sansing2, Amy F. T. Arnsten1, and Dibyadeep Datta1

Abstract
Chronic exposure to uncontrollable stress causes loss of spines and dendrites in the prefrontal cortex (PFC), a recently evolved brain region that provides top-down regulation of thought, action, and emotion. PFC neurons generate top-down goals through recurrent excitatory connections on spines. This persistent firing is the foundation for higher cognition, including working memory, and abstract thought. However, exposure to acute uncontrollable stress drives high levels of catecholamine release in the PFC, which activates feedforward calcium-cAMP signaling pathways to open nearby potassium channels, rapidly weakening synaptic connectivity to reduce persistent firing. Chronic stress exposures can further exacerbate these signaling events leading to loss of spines and resulting in marked cognitive impairment. In this review, we discuss how stress signaling mechanisms can lead to spine loss, including changes to BDNF-mTORC1 signaling, calcium homeostasis, actin dynamics, and mitochondrial actions that engage glial removal of spines through inflammatory signaling. Stress signaling events may be amplified in PFC spines due to cAMP magnification of internal calcium release. As PFC dendritic spine loss is a feature of many cognitive disorders, understanding how stress affects the structure and function of the PFC will help to inform strategies for treatment and prevention.

Keywords
spines, cAMP, calcium, BDNF, actin, mitochondria, complement, microglia, aging, cognition

Received 25 January 2021; accepted 14 June 2021

Introduction
The higher cognitive functions of the recently evolved prefrontal cortex (PFC) are weakened with exposure to stress, reducing top-down regulation and switching control of behavior to more primitive brain circuits. Impaired PFC function can be caused by either a physiological or psychological stress and can occur with even mild, acute psychological stress if the subject feels threatened or out of control. Given the importance of strong PFC function to modern society, these changes are important to understand at the neurobiological level to inform treatment and prevention.

Under optimal conditions, the PFC generates and sustains goals for top-down control, e.g. filtering out irrelevant operations and enhancing processing of relevant stimuli. These functions are often assessed in the laboratory using tests of working memory, attentional regulation, decision-making and extinction of conditioned fear in both animals and humans. Research has shown that these PFC operations can be impaired by exposure to either physiological stressors such as hypoxia, head trauma, or inflammation, or by psychological stressors, where the subject feels little control over the stressful experience.

1Department of Neuroscience, Yale Medical School, New Haven, CT, USA
2Department of Neurology, Yale Medical School, New Haven, CT, USA
Corresponding Author:
Amy F. T. Arnsten, Department of Neuroscience, Yale Medical School, 333 Cedar St., New Haven, CT 06510, USA.
Email: amy.arnsten@yale.edu

Creative Commons CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/creativecommons-at-sage).
The cellular bases for many of these changes are just beginning to be elucidated. However, there are hints that both physiological and psychological stressors may share underlying mechanisms that ultimately lead to the loss of synapses on dendritic spines and the weakening of higher cognitive abilities. Many of these changes are also seen in the aging PFC, where recent data indicate that dysregulation of stress signaling pathways contributes to impaired neuronal firing, loss of synapses, and risk of degeneration with advancing age. The role of chronic physiological and psychological stressors on the long-term structure and function of the PFC is particularly important given our aging society and the increasing burdens of chronic diseases. The following article provides a review of this important and expanding area of neuroscientific research.

A few notes of caution: The research described in this review utilized a variety of experimental conditions, including different 1) species (mouse, rat, rhesus monkey, human), 2) PFC subregions, 3) layers (III vs. V), and 4) stress paradigms. The PFC expands greatly from rodent to monkey to human, with dorsolateral PFC (dlPFC) and frontal pole regions expanding in primates that are not found in rodents. There are also differences in the organization of the medial PFC (mPFC) between rodents and primates that are particularly confusing to the field, where circuit identification will be needed to clarify apparent discrepancies, e.g. whether a PFC neuron excites or inhibits stress actions in amygdala. There are also differences between in vivo vs. in vitro studies, where cell cultures emphasize developmental events that can differ from in vivo conditions. For example, thin spines are immature in cell cultures, but are mature (and predominate) in primate dlPFC. Studies using in vivo neuronal recordings or calcium imaging can be especially affected by laminar differences. For example, physiological recordings in monkey PFC often focus on layer III Delay cells, while recordings from PFC in rodents often capture layer V cells, as layer V is particularly large in rodent mPFC, while layer II/III is small. Calcium imaging in rodents often focuses on layer I, which contains the dendritic tuft of layer V pyramidal cells, while deeper dendrites are not visible. Much of the rodent research on glutamate actions with chronic stress, including interactions with amygdala and the effects of ketamine, have focused on layer V pyramidal cells and their dendritic tuft in layer I. In contrast, rodent research examining the effects of chronic stress on working memory and attention regulation, and the effects of stress-induced catecholamine release, have focused on spine loss from layer II/III pyramidal cells. As layer II/III mPFC is a replicative site of spine loss with chronic stress in rodents, and deep layer III dlPFC microcircuits are central to higher cognition and a focus of spine loss in schizophrenia and aging, layer III is a particular focus of the current review. However, additional research is needed to better bridge across species and circuits, as we are already learning that stress effects are circuit specific. In humans, chronic stress exposure is associated with reduced gray matter volume in dlPFC, and mPFC spine loss from the orbital PFC. We have little knowledge of the neuromodulatory needs of mPFC neurons in primates, and how similar or different they may be to dlPFC or to rodent mPFC. This will be an important area for future research.

Although there may be multiple avenues by which stress initially impacts neuronal physiology, there appear to be final common pathways involved in synapse removal. Thus, the varied effects of chronic stress exposure may ultimately lead to shared mechanisms. This review will first describe the signaling events activated by acute stress exposure that likely lead to spine loss with sustained activation, followed by the mechanisms that may be initiated with chronic stress exposure that lead to actin collapse and phagocytosis by glia, creating the architectural changes seen in the chronically stressed brain.

### Acute, Uncontrollable Stress Weakens PFC and Strengthens More Primitive Circuits

Exposure to even a mild, acute uncontrollable, psychological stressor can rapidly weaken PFC connectivity and cognitive functioning in rodents, monkeys, and humans. A key factor is the subject experiencing themselves as having no control over the stressor, thus initiating monoamine release in the PFC. For example, stressful levels of loud noise (>95dB) impair cognitive performance in rats, monkeys, and humans. Decades of psychological studies in humans have found evidence that uncontrollable psychological stress impairs a variety of cognitive functions that we now know are reliant on the PFC, including performance of the Stroop interference task, working memory, decision-making, and extinction of a conditioned fear response. Functional brain imaging studies have confirmed reductions in dlPFC activity with stress exposure during working memory performance, and suggest that the dlPFC can regulate the visceral stress response via projections to the ventromedial PFC Brodmann Area (BA), which has extensive connections with BA25, a region that becomes overactivated in depression, and mediates the visceromotor outputs from the PFC. Thus, uncontrollable stress has heterogeneous effects on PFC circuits, generally decreasing the activity of those that subserve higher cognition and provide top-
down control of emotion, while increasing the activity of circuits inducing affective, visceral responses.

Studies in animals have revealed some of the neurobiological basis for these rapid changes in higher cognitive abilities. Many of these actions are likely circuit-specific, an arena of recent progress, e.g. with optogenetic identification. Studies in rodents have found increased glutamate release in mPFC during an acute stresor that depends on glucocorticoid stimulation.40,41 Stress-induced glutamate release may involve projections from the amygdala, as part of reciprocal circuits within the mPFC.42 It is unclear if elevated gluta-
mate leads to expanded or atrophied dendrites with chronic stress exposure, which may be circuit-specific.

There is also extensive evidence of stress-induced catecholamine release in PFC arising from brainstem catechol-
amine neurons that are especially sensitive to aversive experience.14,43–45 Catecholamine release in mPFC occurs rapidly with stress onset46 and thus can have immediate effects on cognitive functioning. As reviewed below, high levels of the catecholamines, norepinephrine (NE) and dopamine (DA) in the PFC rapidly activate intracel-
lar stress signaling pathways to weaken PFC synaptic connections and impair PFC cognitive function in pri-
mates, which will be the primary focus of this review.47

Detailed studies of the layer III microcircuits in primate dlPFC that generate mental representations have provided an in-depth understanding of how chemical changes during stress can rapidly impact higher cognitive operations. Under non-stress conditions, extensive, recurrent excitatory connections on spines maintain the persistent firing needed for working memory via NMDAR glutameric synapses on spines, while lateral inhibition from interneurons refines the information held in “mind”.48,49

Layer III dlPFC spines also contain negative feedback mechanisms to prevent seizures in a recurrent excitatory circuit, where feedforward Ca^{2+}-cyclic adenosine monophosphate (cAMP) signaling can increase the open state of nearby potassium (K^{+}) channels to weaken connectivity and reduce firing. The feedback signal may involve Ca^{2+} entry through multiple sources, including the calcium conductance of N-methyl-D-aspartic acid (NMDAR) channels (specifically composed of GluN2B subunits) themselves as well as release from internal storage within the smooth endoplasmic reticulum (SER), called the spine apparatus when it extends into the spine.50–54 As illustrated in Figure 1, there is evidence for feedforward cAMP-Ca^{2+} signaling in dlPFC spines: Ca^{2+} is released through calcium channels on the SER – the inositol trisphosphate receptors (IP3R) and ryanodine receptors (RyR) – which are both localized on the spine apparatus in layer III dlPFC spines.55–57 These spines also express the molecular machinery for cAMP-PKA signaling to magnify internal Ca^{2+} release from the SER spine apparatus through these channels, which in turn can drive more cAMP production, creating a vicious cycle. As shown in Figure 1(a), this molecular machinery is held in check by receptors that inhibit the production of cAMP, i.e. the alpha-2A adrenergic receptor (x2A-AR) and the metabotropic glutamate receptor type 3 (mGluR3), as well as by phosphodiesterase type 4 (PDE4) enzymes, which catabolize cAMP once it is syn-
thesized.21,58,59 Conversely, cAMP-Ca^{2+} signaling is driven by high levels of catecholamines acting through lower affinity NE alpha-1 adrenergic receptors (z1-AR) and DA-1 receptors (D1R) to drive Gq-IP3R-mediated calcium-protein kinase C (PKC) signaling and Gs-
cAMP-PKA signaling, respectively (Figure 1(b)).

cAMP-Ca^{2+} signaling can markedly alter the efficacy of synaptic connections, with moderate levels strengthen-
ing connectivity by increasing calcium near the post-synaptic density, but higher levels weakening connectivity by opening nearby K^{+} channels. As shown in Figure 2, layer III dlPFC spines express K^{+} channels (HCN, KCNQ) whose open states are increased by cAMP-PKA signaling. Under non-stressed, alert conditions (Figure 2(a)), moderate levels of catecholamine release engage high affinity z2A-AR and D1R to dynam-
ically regulate synaptic strength needed for working memory. For example, administration of the z2-AR agonist, guanfacine, systemically or directly into rat or monkey PFC can enhance neuronal firing and improve working memory, attention regulation, and behavioral inhibition.60–66 However, during uncontrollable psychological stress (Figure 2(b)), high levels of catecholamine release engage z1-AR and large numbers of D1R to drive calcium-cAMP-PKA-K^{+} signaling, which rapidly decreases dlPFC neuronal firing and takes the dlPFC “off-line.” dlPFC network connectivity and function can return to normal if PDE4 enzymes catabolize cAMP and normalize intracellular signaling.

Toxic catecholamine actions in PFC also have been seen following traumatic brain injury67–69 and hypoxia,6 suggesting this may be a universal stress response for both psychological and physical stressors. The detrimen-
tal effects of catecholamines in PFC are amplified by glucocorticoids,70 which block catecholamine reuptake into glia.71 In contrast to the PFC, high levels of cate-
cholamines in the amygdala strengthen emotional responses.72 This switches control of brain and behavior from the thoughtful PFC to the reactive amygdala. Similar mechanisms appear to occur in humans, where stress-induced dlPFC dysfunction in working memory is strongly related to a genetic variation in COMT, which increases catecholamine levels.73

**Chronic Stress Causes Loss of Spines**

Chronic exposure to physiological or psychological stressors induces additional alterations, including
initiating mechanisms to remove dendrites and spines from PFC neurons. As schematically illustrated in Figure 2(c), chronic stress weakens connectivity and reduces cell firing by amplifying NE signaling in rat PFC, and increasing KCNQ channel actions, greatly reducing neuronal firing. As reviewed below, sustained elevations in PKC and calcium signaling may lead to a number of additional actions that promote architectural changes in spine structure.

Although loss of spines has been most commonly studied with chronic psychological stressors,16,25,74–77 it has also been observed following hypoxia6 and TBI.8 Loss of dendritic spines and/or dendrites is accompanied by, and often correlates with, the loss of PFC cognitive functioning.15,16,75 For example, Figure 3(a) and (b) show how chronic stress induces spine loss from rat layer II/III mPFC neurons that correlates with loss of working memory abilities. Furthermore, the spine loss and working memory deficits were rescued with chelerythrine, a PKC inhibitor, emphasizing the important functional significance of these architectural changes and the key role of regulatory molecules. (Note that this research has been done in rodents for both practical and humane reasons).

The loss of spines and dendrites with chronic stress is region and circuit specific. Stress-induced dendritic retraction is found in mPFC, and with sufficient stress, in the hippocampus,78 but not in orbital PFC.76 In contrast to the PFC, dendrites actually expand with chronic stress in the amygdala,78 further accentuating the switch from reflective to reflexive state. Even within the mPFC, stress-induced changes are circuit specific. An elegant study by Shansky and colleagues showed that stress reduces dendrites in mPFC neurons involved with cortical-cortical processing, but increases dendrites in the mPFC neurons that project to and excite amygdala actions.25 Shansky also discovered sex differences in these circuits, where females with circulating estrogen had greater responses to stress,79,80 which may arise from their increased responsiveness to catecholamines.81 The molecular mechanisms that lead to expanded vs. atrophied dendrites with chronic stress exposure will be an important area for future research.

Although most of this research has been done in animals, one can also see evidence of reduced connectivity in humans exposed to chronic stress. Analysis of a post-mortem cohort of psychiatric cases where subjects had experienced severe stressors at different stages of life initiated mechanisms to remove dendrites and spines from PFC neurons. As schematically illustrated in Figure 2(c), chronic stress weakens connectivity and reduces cell firing by amplifying NE signaling in rat PFC, and increasing KCNQ channel actions, greatly reducing neuronal firing. As reviewed below, sustained elevations in PKC and calcium signaling may lead to a number of additional actions that promote architectural changes in spine structure.

Figure 1. Regulation of cAMP-Ca\(^{2+}\) signaling in the dendritic spine. (a) Within the dendritic spine, cAMP-Ca\(^{2+}\) signaling is regulated by several key mechanisms to maintain the integrity of calcium homeostasis. Transmission through \(\alpha_2a\)-AR (via norepinephrine (NE)) and mGluR3 (via NAAG), receptors that are positioned in postsynaptic compartments in dlPFC layer III, inhibits cAMP signaling and thus, reduces cAMP-PKA mediated calcium leak into the dendritic spine via phosphorylation of calcium channels (e.g. inositol triphosphate receptors (IP3R) and ryanodine receptors (RyR)) located on the smooth endoplasmic reticulum (SER). Inhibition of cAMP-PKA mediated calcium leak further reduces K\(^+\) channel opening (e.g. HCN and KCNQ), leading to maintenance of working memory. Based on our immunoEM data, we see a decrease in \(\alpha_2a\)-AR localization on the dendritic spines in aged macaques, insinuating a likely loss in calcium regulation. Our immunoEM data has further revealed a constellation of cAMP-related proteins associated with SER within the thin dendritic spines in dlPFC layer III microcircuits. The scaffolding protein disrupted in schizophrenia 1 (DISC1) interacts with phosphodiesterase-4 isozymes (PDE4) to regulate cAMP degradation intracellularly, preventing exacerbated feedforward cAMP-Ca\(^{2+}\) signaling. (b) The dendritic spines also contain calcium regulatory machinery that can conversely drive cAMP-Ca\(^{2+}\) signaling. Higher levels of NE can signal through lower affinity \(\alpha_1\)-AR which can drive Gq-IP3R-mediated calcium-protein kinase C (PKC) signaling, leading to increased cAMP-PKA mediated calcium leak. Higher levels of dopamine (DA) can signal through Dopamine-1 receptor (D1R) on the spine, consequently driving greater calcium leak into the dendritic spine and decreasing dlPFC neuronal firing, impairing working memory.
revealed substantial reductions in mushroom spine density in layer II/III and V of the OFC. 28 This study also found negative correlations between glucocorticoid receptor mRNA/protein expression with total spine density.28 Structural imaging studies have shown reduced PFC gray matter in humans that correlates with the number of aversive events they have experienced. 27,82 Loss of gray matter was especially evident in the mPFC areas (BA32 and BA10m) that mediate interactions between cognitive and affective circuits. Functional imaging studies have also reported reduced functional connectivity with a mild chronic stressor in medical students studying for the medical boards, that recovered once the stress was over.15 The reversal of spine and dendritic loss can also be seen in rodents after extended periods of non-stress,15,77,83 although this resilience decreases with age.83 What causes dendritic spines and dendrites to be lost with extended stress exposure? As described below, there are a number of interacting factors that appear to contribute to dendritic spine removal with chronic stress. ImmunoEM evidence suggests that NE axons actually express more tyrosine hydroxylase with chronic psychological stress exposure,84 and increased catecholamine release in PFC is also seen with hypoxia6 and TBI.67 Thus, a prolonged catecholamine response likely contributes to the pathophysiology of these psychological and physiological stressors. Chronic stress also activates inflammatory signaling that likely contributes to weaker synaptic connections. For example, chronic stress and inflammation increase the production and release of kynurenine acid from astrocytes,85,86 an endogenous metabolite that blocks NMDAR87,88 and impairs PFC working memory function.89 Stress and inflammation also increase the astroglial release of the enzyme GCPII (glutamate carboxypeptidase II).90,91 GCPII hydrolyzes N-acetylaspartylglutamate (NAAG) to glutamate and N-acetylaspartate (NAA), and thus increases

Figure 2. Effects of stress on the synapse in the dlPFC. (a) At the non-stress synapse on the dendritic spine, there is regulated NMDAR transmission with Ca2+ and Na+ with low levels of K+ extrusion through the K+ channels (HCN, KCNQ) as well as low levels of feedforward Ca2+-cAMP signaling. Moderate to low levels of NE signaling through α2A-AR, which inhibits cAMP signaling, allows for enhancement of network firing in the dlPFC by increasing synaptic efficacy for inputs from target neurons. Conversely, moderate to low levels of dopamine (DA) signaling through D1R allows for decreases in synaptic efficacy of the inappropriate neurons. (b) Acute stress drives Ca2+-PKC and cAMP-PKA feedforward signaling via increased dopamine (DA) activation of D1R and norepinephrine (NE) activation of α1AR, respectively. This leads to increased calcium leakage from the SER through Protein Kinase A (PKA)-mediated phosphorylation of IP3R and RyR as well as Protein Kinase C (PKC) activation. Subsequent increases in feedforward calcium-cAMP signaling opens K+ channels and thus, weakens synaptic efficacy and working memory. The perturbation of calcium levels in the spine may promote architectural changes in the spine as well as mitochondrial dysfunction. C. Chronic stress further exacerbates the pathways observed in acute stress. Prolonged Ca2+-cAMP feedforward signaling leads to a decrease in neuronal firing required for higher-order cognition, resulting in working memory deficits, a core cognitive deficit observed in several neuropsychiatric and neurodegenerative diseases. The prolonged Ca2+-cAMP feedforward signaling causes sustained elevations of calcium could further cause perturbations in mitochondria morphology, resulting potentially in the “mitochondria-on-a-string” (MOAS) phenotype.
glutamate concentration at the synapse. Importantly, GCPII prevents NAAG mediated activation of mGluR3, which is located post-synaptically in layer III dlPFC microcircuits, leading to an increase in cAMP concentrations within the spine.59 Both of these chemical changes would weaken the efficacy of NMDAR synaptic transmission in the primate dlPFC, and may lead to additional loss of trophic factors, as described below.

It is possible that a variety of molecular events initiated by stress exposure ultimately lead to similar toxic Ca\(^{2+}\) actions and neuroinflammatory synapse removal. Ca\(^{2+}\) dysregulation has traditionally been considered in terms of glutamate excitotoxicity, with high levels of glutamate stimulation of NMDAR (especially those with GluN2B subunits) causing excessive Ca\(^{2+}\) entry into the cytosol and the initiation of apoptosis to kill the neuron. A lower, nonapoptotic level of Ca\(^{2+}\) entry through NMDAR may be an important initiating event for some PFC neurons that are excited under conditions of stress exposure. However, other PFC pyramidal cells likely show reduced firing and thus reduced glutamate release during stress, e.g. due to increased D1R and a1-AR activation of Ca\(^{2+}\)-cAMP-K\(^{+}\) signaling. In these important microcircuits, the elevated Ca\(^{2+}\) would arise from catecholamine activation of feedforward Ca\(^{2+}\)-cAMP signaling in spines, driving both internal Ca\(^{2+}\) release and Ca\(^{2+}\) entry through voltage-gated channels. Thus, it is possible that the initiating stress signaling events that lead to elevated cytosolic Ca\(^{2+}\) differ between neurons, but that they ultimately engage common final pathways. Furthermore, there may be interactions between seemingly disparate signaling pathways, e.g. where REDD1 (Regulated in Development and DNA Damage responses-1) inhibition of mTOR signaling and subsequent spine loss can be initiated by glucocorticoids,92 but may also be driven by PKA activation of REDD1 following high levels of catecholamine release.47 Altogether, the evidence suggests multiple interacting pathways that lead to a similar phenotype of spine loss in the neural circuits that normally provide top-down regulation of emotion, thus disinhibiting the brain's stress response.

The following sections below summarize current literature and proposed hypotheses on how sustained high levels of feedforward, Ca\(^{2+}\)-PKC-cAMP-PKA signaling and weakened synaptic transmission, or sustained Ca\(^{2+}\) entry through NMDAR, may lead to loss of trophic factors, actin depolymerization, mitochondrial changes and the induction of inflammatory mechanisms to remove PFC connections during chronic stress exposure.

### Potential Mechanisms Involved With Spine Removal

#### Weaker Synaptic Transmission Leading to Loss of BDNF

Brain-derived neurotrophic factor (BDNF) is a versatile neurotrophin contributing to brain development, neuronal survival, and maintenance of dendritic arborization and plasticity in the CNS.93-95 It is expressed across all regions in the brain, but it is highly expressed within the
BDNF exists in numerous functional isoforms, each with variable levels of expression across brain regions. Pro-BDNF consists of both the pro-domain and a mature domain that can either be cleaved to form mature BDNF (mBDNF) and BDNF pro-peptide or secreted as its own functional protein. Pro-BDNF and mBDNF have unique targets: the p75 neurotrophin receptor (p75NTR) and tropomyosin-related kinase B (TrkB) receptor, respectively. Generally, the functions of pro-BDNF and mBDNF are often seen at odds with one another. For instance, pro-BDNF can elicit long term depression (LTD) in the hippocampus, while mBDNF primarily elicits long term potentiation (LTP) in the hippocampus. These interactions lead to a diverse host of downstream signaling cascades that can regulate transcription factors and ultimately, synaptic activity.

How does BDNF affect the synapse at the structural level? BDNF is thought to play a role in both spino-genesis as well as maintenance of mature spines. For instance, several studies have shown that the long-term administration of BDNF in primary rodent pyramidal hippocampal neurons or cerebellar purkinje neurons leads to increased dendritic spine density. Studies have found this to be directly mediated through TrkB signaling, as Trk receptor antagonists can directly prevent the BDNF-induced increase in spine density. At the same time, in vivo and in vitro studies have demonstrated the ability for BDNF to alter the morphology of spines, altering post-synaptic densities and neurotransmitter receptor distributions. For example, gradual BDNF administration to primary hippocampal neurons led to spine neck elongation. It is noteworthy, however, to mention that increase in spine density secondary to exogenous application of BDNF is not appreciated in all the various culture and slice studies, which highlights the complexity of how BDNF’s effects are modulated (for comprehensive reviews on BDNF, see Kowiański et al. and Kellner et al.). Notably, the majority of the literature has focused on the effects of exogenous BDNF, since homozygous BDNF KO mutations are lethal. However, studies using heterozygous BDNF KO mice and inhibitors of TrkB, for example, have begun to elucidate the nature of endogenous BDNF. Nevertheless, it is evident that BDNF seems to be critical in supporting the development and maintenance of dendritic spines at the synapse.

Yet another important consideration regarding BDNF is the various pools of BDNF acting at the synapse, e.g. from presynaptic terminals, postsynaptic dendrites, astrocytes, and microglia. For instance, in addition to BDNF release from the presynaptic terminal onto post-synaptic TrkB receptors, BDNF may also be released by glia and by the post-synaptic compartment (Figure 4) at low but physiologically important levels for maintaining synaptic integrity. Recognizing that BDNF can come from several local sources at the synapse has profound clinical implications for treatments as they converge on BDNF modulation.

What are the mechanisms that mediate BDNF expression? There is a large body of literature demonstrating a strong correlation between neuronal activity and BDNF transcription and secretion. Various paradigms simulating increased neuronal activity have
demonstrated upregulation of BDNF transcription. For instance, BDNF transcription is seen during kindling, LTP induction, in vivo associative learning, and membrane depolarization. Furthermore, animal and in vitro studies have revealed that neuronal activity also regulates secretion of BDNF. While there is experimental support for the activity-dependent modulation of BDNF, this work has primarily been in the hippocampus and the cortex. Thus, there remains much work to be done to expand the scope of examined regions in order to understand how region-specific activity can regulate BDNF.

Accumulating data suggest that reductions in BDNF with chronic stress may contribute to loss of dendritic spines. These studies have utilized a variety of chronic stress paradigms (e.g., foot shock, swim stress, restraint stress, social isolation, etc.) over a wide temporal scale (ranging from 7 to 21 days) and have largely observed decreased levels of BDNF. For example, daily restraint of rats for 3 weeks resulted in decreased BDNF mRNA in the hippocampus and the subsequent atrophy of hippocampal pyramidal neuron dendrites. However, an important limitation of these studies is the scope of regions and cell types examined. This is critical, since the role of BDNF is circuit-specific. For instance, chronic stress in rodents leads to a decrease in BDNF and TrkB mRNA in the hippocampus, but leads to an increase in BDNF mRNA expression in the amygdala and nucleus accumbens. This difference harkens back to our brain’s ability to rapidly switch from a reflective to a reflexive state, which necessitates different underlying circuitry for the regions involved. BDNF signaling may be altered by catecholamine mechanisms, where mechanisms that promote connectivity also amplify BDNF. For example, a study investigating PFC neurodegeneration in the setting of hypobaric hypoxia in layer II of rat mPFC found that administering guanfacine increased the anti-apoptotic Bcl2 and BDNF and decreased pro-apoptotic Bax and caspase. Thus, catecholamine actions may have widespread influences on dendritic spine health through regulation of BDNF signaling.

BDNF may also influence synaptic health via mTOR (Mammalian Target of Rapamycin) signaling, which regulates local protein synthesis to facilitate synaptic plasticity. mTOR is strongly activated by BDNF/TrkB signaling and thus, likely links BDNF and synaptic plasticity. Conversely, chronic stress upregulates REDD1, which inhibits mTOR via the mTORC1 subunit. The work of Duman and colleagues have summarized how AMPAR signaling can increase the translation of BDNF in spines, leading to BDNF release and engagement of TrkB receptors that activate mTORC1 signaling to increase the production of synaptic proteins (Figure 4). This model depicts a traditional synapse, where NMDAR are extrasynaptic, and inhibit BDNF translation (Figure 4). Thus, ketamine blockade of NMDAR in these circuits would promote synaptic growth, e.g. in mPFC neurons that express DA D1R and project to the amygdala and are needed for ketamine’s beneficial actions in mice. However, the reader is cautioned that recently evolved circuits in primate layer III dPFC are very different, with NMDAR exclusively in the synapse, and having little reliance on AMPAR. As a result, it is likely that NMDAR would enhance rather than impede BDNF actions in these circuits. Thus, molecular mechanisms may differ substantially in recently evolved primate circuits.

Human studies echo the findings from research in animals. For example, postmortem PFC of human subjects with Major Depressive Disorder (MDD), similar to stressed rodents, have reduced levels of BDNF, elevated levels of REDD1, and decreased levels of mTOR. Conversely, the antidepressant treatment response paralleled an increase in BDNF mRNA levels in the hippocampus and PFC. There are also relationships to aging, as a cohort study following over 500 aged participants until death revealed that a higher level of brain BDNF expression was associated with a slower rate of cognitive decline.

Altogether, BDNF signaling is complex and the extent of its capabilities not fully understood, but it is vital to the synapse. And while reduced BDNF appears to contribute to synaptic loss under chronic stress, the specific pathways facilitating this loss have yet to be elucidated.

Changes in the Actin Cytoskeleton

Actin is a critical component of the dendritic spine’s ability to alter its structure in response to synaptic signaling and mediate synapse stability. Dendritic spines are built on a complex network of branched and linear filamentous (F)-actin that form the basis of the spine shape, including stable vs. dynamic changes in spine morphology. As a result, alterations in actin may contribute to loss of dendritic spines during chronic stress. Molecular regulation of the actin cytoskeleton is complex, but can be linked to signaling cascades known to be activated by chronic stress exposure.

One mechanism that likely impacts actin is the increase in PKC signaling during stress exposure, which has been found in both rodent and macaque PFC. Inhibition of PKC signaling prevents spine loss with chronic stress, highlighting its importance. PKC phosphorylates several substrates that directly affect the morphology of actin cytoskeleton. One substrate is myristoylated alanine-rich C kinase substrate (MARCKS). As illustrated in Figure 5,
MARCKS directly stabilizes F-actin by connecting the cytoskeleton to the spine membrane, but this stabilizing function is lost when MARCKS is phosphorylated by PKC. In in vitro rat hippocampal cultures, depletion of MARCKS resulted in loss of spine density, width and length of the dendritic spines. Adducin is yet another known substrate of PKC and is critical in assembling the spectrin-actin network, providing physical support, as well as capping the fast-growing ends of actin filaments. Importantly, it is enriched in dendritic spines and has been found to be important in synapse formation and stabilization, while PKC phosphorylation of adducin causes spine disassembly. Thus, increased levels of PKC during chronic stress may disrupt a number of regulators of the actin skeleton leading to architectural collapse of the dendritic spine.

As shown in Figure 5, BDNF is also known to influence actin stability through TrkB receptor signaling. BDNF can stimulate the recruitment of RHO-family GTPase (RAC1), leading to activation of serine/threonine-protein kinase (PAK) and LIM domain kinase 1 (LIMK1) which can phosphorylate and inhibit cofilin1, thus blocking its ability to sever actin filaments. This cascade of events was tested in rat primary neuron cultures, which demonstrated that LIMK1 translation was dependent on BDNF and directly led to phosphorylation of cofilin1 at Ser-3, locally in the dendrites, which increased spine size and stability.

Figure 5. Roles of PKC and BDNF on maintenance of the actin cytoskeleton in the dendritic spine. Protein Kinase C (PKC) and Brain-derived neurotrophic factor (BDNF) regulate and maintain the actin cytoskeleton in the dendritic spine. PKC can interact directly with actin regulating proteins by phosphorylating them. Myristoylated alanine-rich C kinase substrate (MARCKS) is a F-actin cross-linking protein acting as a bridge connecting the actin cytoskeleton directly to the dendritic spine membrane. Furthermore, it can promote actin polymerization. Upon phosphorylation by PKC, MARCKS is redistributed from the plasma membrane to the cytoplasm and unable to bind to F-actin. PKC can also alter actin indirectly, e.g. through phosphatidylinositol 4,5-biphosphate (PIP2) actions. In the setting of increased stress, high levels of catecholamines, including norepinephrine (NE), can act through lower affinity alpha-1 adrenergic receptors (α1-AR) to drive Gq-IP3R-mediated calcium-protein kinase C (PKC) signaling. In both stressed rodent and macaque models, PKC expression is increased in PFC. The increased PKC signaling could lead to actin cytoskeletal disruption resulting in dendritic spine instability. BDNF is a versatile molecule that can influence actin cytoskeleton through TrkB receptor signaling. Downstream of TrkB receptor signaling leads to recruitment of RHO-family GTPase (RAC1), leading to activation of serine/threonine-protein kinase (PAK) and LIM domain kinase 1 (LIMK1) which can phosphorylate and inhibit cofilin1, thus blocking its ability to sever actin filaments. Another pathway downstream of BDNF-TrkB signaling is the recruitment of cortactin, an F-actin binding protein. Cortactin activates and stabilizes actin-related protein 2/3 (ARP2/3) complex for nucleation of actin filaments, which is necessary for formation of new actin filament branches. In the setting of increased, persistent stress, we see alterations of BDNF expression, notably decreases in BDNF expression. This could have significant downstream consequences for the actin cytoskeleton structure of dendritic spines.
This is likely because actin cytoskeleton is dynamically modulated and thus, at different stages of disease, requires preferential activated or inactivated forms.

There are changes in actin regulatory molecules in brains of patients with mental disorders, such as schizophrenia.190–192 For instance, transcription levels of ARP2/3 complex subunits and nucleation promotion factors were significantly decreased in layer III pyramidal cells of the dlPFC from patients with schizophrenia.193 Schizophrenia is also associated with alterations in the actin cytoskeleton and has been implicated in genetic studies of schizophrenia.194–196 Thus, these changes in actin mechanisms are perhaps key in understanding the dendritic spine loss that is seen in schizophrenia and bipolar disorder among other mental disorders.197,198

**Calcium Dysregulation Leading to MOAS and Inflammation**

In addition to the direct effects of PKC signaling on actin dynamics, elevated cytosolic calcium levels can induce a series of events to activate inflammatory signaling and the removal of afflicted synapses. Very high levels of cytosolic calcium can induce apoptotic cell death, e.g. caused by excitotoxicity in neuronal cultures. However, most cognitive disorders do not involve apoptotic cell death, but demonstrate early dendritic atrophy. This may arise from more subtle, sustained increases in cytosolic calcium, e.g. from chronic stress or aging. Calcium dysregulation can arise from numerous sources, including reductions in calcium binding proteins, reduced regulation of cAMP-drive on internal calcium release, and increased flux through calcium channels. For example, stress or age can increase calcium efflux from the SER through RyR and IP3R, and lead to elevated cytosolic calcium.21,199–205

Elevated calcium can lead to calcium overload of mitochondria. Mitochondria are essential organelles that support neurons by directing energy metabolism, cellular respiration, reactive oxygen species (ROS) generation and dissipation, and calcium homeostasis.206,207 They are highly dynamic organelles, undergoing fission and fusion depending on energetic demands of the cell. These functions ultimately can determine the fate of the neuron, leading the neuron to apoptosis or synaptic loss when they are perturbed.207–209 Given the versatile nature of mitochondria, they can serve as an important indicator of the health of the cell.

Calcium is a critical substrate for mitochondria that can disrupt oxidative phosphorylation leading to release of ROS and nitric oxide. Calcium crosses the outer mitochondrial membrane (OMM) through the voltage-dependent anion channel (VDAC) and across the inner mitochondrial membrane (IMM) through the mitochondrial Ca$^{2+}$ uniporter (MCU).209 Calcium enters the mitochondrion through ER-coupling sites called mitochondria-associated membranes (MAMs).210–212 MAMs are critical sites for lipid, phospholipid, and Ca$^{2+}$ exchange from the ER to the mitochondria which can support neurotransmission, bioenergetics, and apoptosis initiation.210–214 Mitochondria are also ideally positioned near regions of high Ca$^{2+}$ levels, allowing calcium concentrations to reach concentrations 5- to 10-fold higher than that of calcium in the cytosol.215–218 This, however, is a point of debate as some studies have suggested that high Ca$^{2+}$ levels in fact draw mitochondria to those regions.219 Nevertheless, the general consensus is that mitochondria play a critical role in regulating calcium levels, and that calcium in turn can alter mitochondrial function.

Synapses are especially dependent on mitochondria for the necessary large amounts of ATP and thus, synapses may be particularly susceptible to disruptions in calcium regulation. For instance, when mitochondria sense an excess of Ca$^{2+}$, this can lead to increased formation of mitochondrial permeability transition pores (mPTP) which can trigger a loss in mitochondrial membrane potential, reduced ATP formation, and a cascade of inflammatory events.220 Abnormal mitochondria can also take on dysmorphic morphologies.221–224 The Zhang group has identified one abnormal mitochondrial phenotype as “Mitochondria-on-a-string” (MOAS).225–226 MOAS are defined as long mitochondrion with bulbous segments of the organelle and connected by highly constricted segments, e.g. as schematically illustrated in Figure 2(c). As proposed in Figure 6, MOAS may arise from disruptions in calcium flux and bioenergetic stress leading to an interruption of fission.221,227–229 Consistent with this hypothesis, we have observed MOAS within the dendritic shafts of glutamergic-like pyramidal neurons within layer III of the dlPFC of aged rhesus macaques, with pinched “string” regions next to calcium-containing SER.223 Especially relevant to the loss of spines, calcium overload of mitochondria can elevate the release of ROS, which can initiate production of pro-inflammatory cytokines, such as activation of the NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome.230–233 Further investigation is necessary, however, on how these prolonged pro-inflammatory signals can ultimately lead to the removal of the synapse. We explore this in the next section.

**MOAS and Inflammation Engaging Phagocytosis by Glia**

Glia account for approximately 50% of the cells present in the brain, and include oligodendrocytes, ependymal cells, microglia, and astrocytes.234–236 They provide fundamental support for neuronal health and function, including elimination of inappropriate synapses by astrocytes237 and by microglia.238 While synaptic
elimination and glial participation have been best characterized at the neuromuscular junction (NMJ) in the PNS, there is growing evidence for glial involvement during synaptic elimination in the CNS. 239–245 Synaptic elimination has been studied in the developing CNS and in CNS disorders. For example, glial phagocytosis of synapses has been documented in various pathological conditions, e.g., Alzheimer’s Disease (AD), Huntington’s Disease (HD), Parkinson’s Disease (PD), and schizophrenia, all of which have underlying synaptic dysfunction. 246–251 Many studies have begun to identify the molecules that facilitate glial phagocytosis, but chief
among them are complement proteins. Genetic association studies suggest that complement signaling may be a key factor in the activation of microglia and astrocytes to remove synapses. For example, in schizophrenia there is a strong genetic association with complement C4a (a gene encoding a complement component), while Complement Receptor 1 (CR1) is associated with increased risk of AD.

Complement signaling is one of the key arms of the innate immune system, allowing our immune system to quickly identify and remove foreign antigens. The classical pathway of complement activation is initiated by C1q, which leads to activation of downstream complement components, importantly C3 and C4, which can then signal to microglia through their receptors. It is also possible that C1q engages other immune pathway receptors, such as major histocompatibility complex I (MHC I) on neurons.

The role of complement signaling in the brain has been largely studied in developmental models where inappropriate synapses are pruned by glia. For instance, Stevens et al. first noted the production of complement C1q in Retinal Ganglion Cells during the critical period in visual development in mice. The Stevens group also determined the role of microglial C3 in activity-dependent synaptic pruning in the developing retinogeniculate system and found that the upregulation in neuronal C1q was regulated by astrocytic release of TGF-ß (a growth factor), thus implicating both glial subsets in coordinating synaptic removal. C1q and C4 have been found to increase with age, especially in AD vulnerable regions like the hippocampus, while C3 has been shown to decrease with age. Additionally, the mRNA for complement proteins is appreciably increased in early and late stage AD brains. Furthermore, the genetic depletion of C1q in AD mouse models (APP and APP/PS1) has been found to decrease neuronal injury and reduce the numbers of activated microglia surrounding the AB plaques. However, there is also some evidence that C3 and C5 can be neuroprotective in AD, since C1q can enhance phagocytosis and clear apoptotic and cellular debris. As a result, these studies seem to suggest the importance of complement proteins and the complement cascade in AD pathology, and more specifically synaptic health. It is also likely playing a dual – neuroprotective and neuropathological role, e.g. by removing both injured and functional synapses.

We have seen the presence of C1q in the aged macaque dlPFC in glial profiles, as expected, but also in three separate neuronal compartments (spine head, presynaptic axon terminus, and in the dendritic shaft next to dysmorphic mitochondria-on-a-string “MOAS”). These data suggest that calcium overload in pyramidal cell spines can lead to dysmorphic mitochondria in neighboring dendrites, which then induce the expression of C1q to label nearby synapses for removal by glia. This hypothesis is depicted in Figure 5 and indicates an important area for further research.

### Relevance to Mental Disorders and Their Treatment

Understanding the molecular mechanisms underlying spine removal may provide treatment strategies for those exposed to psychological or physiological trauma. For example, inhibiting cAMP-PKA signaling with a2-AR agonists prevents PFC spine loss in rats, and these agents are useful in treating traumatized children. Similarly, inhibition of PKC signaling protects spines and cognition in rats, and treatments for bipolar disorder such as lithium that reduce PKC signaling protect PFC gray matter in patients. Finally, both typical antidepressants and ketamine can restore spine numbers in stressed rodents, the latter via mTOR signaling. Taken together,

### Table 1. Outstanding questions.

| Question                                                                 | Description                                                                                     |
|-------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| How are medial PFC circuits in primates regulated at the molecular level? | Do these differ between subregions such as BA24 vs. BA25 vs. BA32? How do these compare to data from mPFC circuits in rodents and to layer III dlPFC in primates? |
| How can we reverse the synaptic loss seen with chronic stress?          | At what point are the changes seen with chronic stress irreversible? How might we be able to predict those with increased susceptibility to the detrimental sequelae of chronic stress? |
| What dictates the temporal course of the synaptic changes seen with chronic stress? | How are the mechanisms that mediate BDNF heterogeneity across the brain maintained? What are the in vivo functional consequences of each of the various sources of BDNF biosynthesis and secretion locally at the synapse? What are the signals that coordinate the interactions among astrocytes, microglia, and the synapses? How are they altered across different brain regions and within specific laminar locations? Is microglial phagocytosis of the synapses driving synaptic loss or removing the toxic debris? What are the shared and unique mechanisms for microglia-mediated phagocytosis during neurodevelopment vs. age-related phenotypes? How can we harness novel single cell spatial transcriptomics technology to disentangle these different cell type interactions, given these local changes at the ultrastructure level? |
these data suggest that understanding how stress alters PFC circuits has relevance to human disorders.

**Concluding Remarks**

The PFC provides top-down regulation of thought, action and emotion, allowing us to adapt and function in our increasingly information-driven, inter-connected society. In recent years, we have begun to identify the components of the underlying molecular machinery that provide strong dIPFC function, as well as the active mechanisms for weakening neuronal firing and removing synaptic connections during stress. Significant advances have been made in understanding how stress can change the circuitry, synaptic density, signal transmission, and cell-to-cell interactions in the PFC. We highlight a few questions that require further illumination in Table 1. Understanding the role of stress signaling pathways in the recently evolved PFC can shed light on why these circuits are especially vulnerable across numerous neurological disorders and provide strategies for therapeutic interventions.

**Acknowledgments**

The authors would like to dedicate this work to the memory of Ronald Duman, who made groundbreaking studies on the mechanisms underlying stress-related spine loss and their recovery with antidepressant medications.

**Declaration of Conflicting Interests**

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Yale University and AFTA receive royalties from Shire/Takeda from the USA sales of extended release guanfacine (Intuniv). They do not receive royalties from international nor generic sales of Intuniv.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: EW has been supported by training grant 1T32GM136651-01; AFTA is supported by R01 AG061190-01 and NSF 20,15,276; LHS is supported by NIH R01NS097728, R01NS095993, U01NS113445 and AHA EIA34770133; DD is supported by NIH R01NS097728, R01NS095993, AFTA is supported by R01 AG061190-01 and NSF 20,15,276; EW has been supported by training grant 1T32GM136651-01; for the research, authorship, and/or publication of this article: Yale University and AFTA receive royalties from Shire/Takeda from the USA sales of extended release guanfacine (Intuniv). They do not receive royalties with respect to the research, authorship, and/or publication of this article: Yale University and AFTA receive royalties from Shire/Takeda from the USA sales of extended release guanfacine (Intuniv). They do not receive royalties from international nor generic sales of Intuniv.

**ORCID iD**

Amy F. T. Arnsten https://orcid.org/0000-0002-3420-1308

**References**

1. Fuster JM. *The Prefrontal Cortex*. 4th ed., reprint. Amsterdam: Elsevier, Academic Press; 2009.

2. Goldman-Rakic PS. The ‘psychic cell’ of ramón y cajal. *Prog Brain Res.* 2002; 136: 427–434.

3. Robbins TW. Dissociating executive functions of the frontal cortex. *Philos Trans R Soc Lond B Biol Sci.* 1996; 351: 1463–1470; discussion 1470–1471.

4. Szczepanski SM, Knight RT. Insights into human behavior from lesions to the prefrontal cortex. *Neuron.* 2014; 83(5): 1002–1018.

5. Kauer H, Sahu S, Panjwani U. Guanfacine promotes neuronal survival in medial prefrontal cortex under hypobaric hypoxia. *Brain Res.* 2016; 1636: 152–160.

6. Kauer H, Sahu S, Kumar S, Panjwani U. Guanfacine is an effective countermeasure for hypobaric hypoxia-induced cognitive decline. *Neuroscience.* 2013; 254: 110–119.

7. Hoskison MM, Moore AN, Hu B, Orsi S, Kobori N, Dash PK. Persistent working memory dysfunction following traumatic brain injury: evidence for a time-dependent mechanism. *Neuroscience.* 2009; 159(2): 483–491.

8. Zhao J, Huynh J, Hylin MJ, et al. Mild traumatic brain injury reduces spine density of projection neurons in the medial prefrontal cortex and impairs extinction of contextual fear memory. *J Neurotrauma.* 2018; 35(1): 149–156.

9. Shen X, Sun Y, Wang M, et al. Chronic N-acetylcystein treatment alleviates acute lipopolysaccharide-induced working memory deficit through upregulating caveolin-1 and synaptophysin in mice. *Psychopharmacology (Berl).* 2018; 235(1): 179–191.

10. Reim B, Glass DC, Singer JE. Behavioral consequences of exposure to uncontrollable and unpredictable noise. *J Appl Social Psychol.* 1971; 1(1): 44–56.

11. Minor TR, Jackson RL, Maier SF. Effects of task-irrelevant cues and reinforcement delay on choice-escape learning following inescapable shock: evidence for a deficit in selective attention. *J Exp Psychol Anim Behav Process.* 1984; 10(4): 543–556.

12. Arnsten AF. The biology of being frazzled. *Science.* 1998; 280(5370): 1711–1712.

13. Maier SF, Amat J, Baratta MV, Paul E, Watkins LR. Behavioral control, the medial prefrontal cortex, and resilience. *Dialogues Clin Neurosci.* 2006; 8(4): 397–406.

14. Arnsten AFT. Stress signalling pathways that impair prefrontal cortex structure and function. *Nat Rev Neurosci.* 2009; 10(6): 410–422.

15. Liston C, McEwen BS, Casey BJ. Psychosocial stress reversibly disrupts prefrontal processing and attentional control. *Proc Natl Acad Sci USA.* 2009; 106(3): 912–917.

16. Hains AB, Vu MAT, Maciejewski PK, van Dyck CH, Gottron M, Arnsten AFT. Inhibition of protein kinase C signaling protects prefrontal cortex dendritic spines and cognition from the effects of chronic stress. *Proc Natl Acad Sci USA.* 2009; 106(42): 17957–17962.

17. Kecojevic A, Basch CH, Sullivan M, Davi NK. The impact of the COVID-19 epidemic on mental health of undergraduate students in New Jersey, cross-sectional study. *PLoS One.* 2020; 15(9): e0239696.

18. Conti C, Fontanesi L, Lanzara R, Rosa I, Porcelli P. Fragile heroes. The psychological impact of the
COVID-19 pandemic on health-care workers in Italy. *PLoS One.* 2020; 15(11): e0242538.

19. Morrison JH, Baxter MG. The ageing cortical synapse: hallmarks and implications for cognitive decline. *Nat Rev Neurosci.* 2012; 13(4): 240–250.

20. Wang M, Gamo NJ, Yang Y, et al. Neuronal basis of age-related working memory decline. *Nature.* 2011; 476(7359): 210–213.

21. Carlyle BC, Nairn AC, Wang M, et al. cAMP-PKA phosphorylation of tau confers risk for degeneration in aging association cortex. *Proc Natl Acad Sci U S A.* 2014; 111(13): 5036–5041.

22. Datta D, Leslie SN, Morozov YM, et al. Classical complement cascade initiating C1q protein within neurons in the aged rhesus macaque dorsolateral prefrontal cortex. *J Neuroinflammation.* 2020; 17(1): 8.

23. Wise SP. Forward frontal fields: phylogeny and fundamental function. *Trends Neurosci.* 2008; 31(12): 599–608.

24. Wallis CU, Cardinal RN, Alexander L, Roberts AC, Clarke HF. Opposing roles of primate areas 25 and 32 and their putative rodent homologs in the regulation of negative emotion. *Proc Natl Acad Sci USA.* 2017; 114(20): E4075–E4084.

25. Shansky RM, Hamo C, Hof PR, McEwen BS, Morrison JH. Stress-induced dendritic remodeling in the prefrontal cortex is circuit specific. *Cereb Cortex N Cortex* 2009; 19 (10): 2479–2484.

26. Blix E, Perski A, Berglund H, Savic I. Long-Term Occupational Stress Is Associated with Regional Reductions in Brain Tissue Volumes. *PLoS One.* 2013; 8(6): e64065.

27. Ansell EB, Rando K, Tuit K, Guarnaccia J, Sinha R. Cumulative adversity and smaller gray matter volume in medial prefrontal, anterior cingulate, and insula regions. *Biol Psychiatry.* 2012; 72(1): 57–64.

28. Kaul D, Smith CC, Stevens J, et al. Severe childhood and adulthood stress associates with neocortical layer-specific reductions of mature spines in psychiatric disorders. *Neurobiol Stress.* 2020; 13: 100270.

29. Arnsten AF, Berridge C, Segal DS. Stress produces opioid-like effects on investigatory behavior. *Pharmacol Biochem Behav.* 1985; 22(5): 803–809.

30. Arnsten AF, Goldman-Rakic PS. Noise stress impairs prefrontal cortical cognitive function in monkeys: evidence for a hyperdopaminergic mechanism. *Arch Gen Psychiatry.* 1998; 55(4): 362–368.

31. Hartley LR, Adams RG. Effect of noise on the stroop test. *J Exp Psychol.* 1974; 102(1): 62–66.

32. Lue thin M, Meier B, Sandi C. Stress effects on working memory, explicit memory, and implicit memory for neutral and emotional stimuli in healthy men. *Front Behav Neurosci.* 2008; 2: 5.

33. Lenow J, Constantino SM, Daw ND, Phelps EA. Chronic and Acute Stress Promote Overexploitation in Serial Decision Making. *J Neurosci.* 2017; 37(23): 5681–5689.

34. Rao CM, Phelps EA. The influence of acute stress on the regulation of conditioned fear. *Neurobiol Stress.* 2015; 1: 134–146.

35. Qin S, Hermans EJ, van Marle HJF, Luo J, Fernández G. Acute psychological stress reduces working memory-related activity in the dorsolateral prefrontal cortex. *Biol Psychiatry.* 2009; 66(1): 25–32.

36. Sinha R, Lacadie CM, Constable RT, Seo D. Dynamic neural activity during stress signals resilient coping. *Proc Natl Acad Sci U S A.* 2016; 113(31): 8837–8842.

37. Ongür D, Price JL. The organization of networks within the orbital and medial prefrontal cortex of rats, monkeys and humans. *Cereb Cortex.* 2000; 10: 206–219.

38. Joyce MKP, Barbas H. Cortical connections position primate area 25 as a keystone for interoception, emotion, and memory. *J Neurosci.* 2018; 38(7): 1677–1698.

39. Mayberg HS, Lozano AM, Voon V, et al. Deep brain stimulation for treatment-resistant depression. *Neuron.* 2005; 45(5): 651–660.

40. Moghaddam B, Bolinao ML, Stein-Behrens B, Sapolsky R. Glucocorticoids mediate the stress-induced extracellular accumulation of glutamate. *Brain Res.* 1994; 655(1-2): 251–254.

41. Musazzi L, Treccani G, Poli M. Functional and structural remodeling of glutamate synapses in prefrontal and frontal cortex induced by behavioral stress. *Front Psychiatry* 2015; 6: 60.

42. Liu W-Z, Zhang W-H, Zheng Z-H, et al. Identification of a prefrontal cortex-to-amygdala pathway for chronic stress-induced anxiety. *Nat Commun.* 2020; 11(1): 2221.

43. Ida Y, Elsworth JD, Roth RH. Anxiogenic beta-carboline FG 7142 produces activation of noradrenergic neurons in specific brain regions of rats. *Pharmacol Biochem Behav.* 1991; 39(3): 791–793.

44. Deutch AY, Roth RH. The determinants of stress-induced activation of the prefrontal cortical dopamine system. *Prog Brain Res.* 1990; 85: 367–402; discussion 402–403.

45. Finlay JM, Zigmond MJ, Abercrombie ED. ED. Increased dopamine and norepinephrine release in medial prefrontal cortex induced by acute and chronic stress: effects of diazepam. *Neuroscience.* 1995; 64(3): 619–628.

46. Nakane H, Shimizu N, Hori T. Stress-induced norepinephrine release in the rat prefrontal cortex measured by microdialysis. *Am J Physiol.* 1994; 267(6 Pt 2): R1559–R1566.

47. Arnsten AFT. Stress weakens prefrontal networks: molecular insults to higher cognition. *Nat Neurosci.* 2015; 18(10): 1376–1385.

48. Goldman-Rakic PS. Cellular basis of working memory. *Neuron.* 1995; 14(3): 477–485.

49. González-Burgos G, Barrionuevo G, Lewis DA. Horizontal synaptic connections in monkey prefrontal cortex: an in vitro electrophysiological study. *Cereb Cortex.* 2000; 10: 82–92.

50. Dumas TC. Developmental regulation of cognitive abilities: modified composition of a molecular switch turns on associative learning. *Prog Neurobiol.* 2005; 76(3): 189–211.
51. Kristiansen LV, Patel SA, Haroutunian V, Meadow-Woodruff JH. Expression of the NR2B-NMDA receptor subunit and its Tbr-1/CINAP regulatory proteins in post-mortem brain suggest altered receptor processing in schizophrenia. *Synapse*. 2010; 64(7): 495–502.
52. Wang H, Stradtman GG, Wang X-J, Gao W-J. A specialized NMDA receptor function in layer 5 recurrent microcircuitry of the adult rat prefrontal cortex. *Proc Natl Acad Sci U S A*. 2008; 105(43): 16791–16796.
53. Wang M, Yang Y, Wang C-J, et al. NMDA receptors subserve persistent neuronal firing during working memory in dorsolateral prefrontal cortex. *Neuron*. 2013; 77(4): 736–749.
54. Wang XJ. Synaptic reverberation underlying mnemonic persistent activity. *Trends Neurosci*. 2001; 24(8): 455–463.
55. Chen N, Luo T, Raymond LA. Subtype-dependence of NMDA receptor channel open probability. *J Neurosci*. 1999; 19(16): 6844–6854.
56. Nishiyama M, Hong K, Mikoshiba K, Poo M, Kato K. Calcium stores regulate the polarity and input specificity of synaptic modification. *Nature*. 2000; 408(6812): 584–588.
57. Sheng M, Cummings J, Roldan LA, Jan YN, Jan LY. Changing subunit composition of heteromeric NMDA receptors during development of rat cortex. *Nature*. 1994; 368(6467): 144–147.
58. Wang M, Ramos BP, Paspalas CD, et al. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. *Cell*. 2007; 129(2): 397–410.
59. Jin LE, Wang M, Galvin VC, et al. mGluR2 versus mGluR3 metabotropic glutamate receptors in primate dorsolateral prefrontal cortex: postsynaptic mGluR3 strengthen working memory networks. *Cereb Cortex*. 2018; 28(3): 974–987.
60. Arnsten AF, Cai JX, Goldman-Rakic PS. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. *J Neurosci*. 1988; 8(11): 4287–4298.
61. Arnsten AF, Contant TA. Alpha-2 adrenergic agonists decrease distractibility in aged monkeys performing the delayed response task. *Psychopharmacology (Berl)*. 1992; 108(1-2): 159–169.
62. O’Neill J, Fitten LJ, Siembieda DW, Ortiz F, Halgren E. Effects of guanfacine on three forms of distraction in the aging macaque. *Life Sci*. 2000; 67(8): 877–885.
63. Wang M, Tang Z-X, Li B-M. Enhanced visuomotor associative learning following stimulation of alpha 2A-adrenoceptors in the ventral prefrontal cortex in monkeys. *Brain Res*. 2004; 1024(1-2): 176–182.
64. Steere JC, Arnsten AF. The alpha-2A noradrenergic receptor agonist guanfacine improves visual object discrimination reversal performance in aged rhesus monkeys. *Behav Neurosci*. 1997; 111(5): 883–891.
65. Engberg G, Eriksson E. Effects of alpha 2-adrenoceptor agonists on locus coeruleus firing rate and brain noradrenaline turnover in N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ)-treated rats. *Naunyn Schmiedebergs Arch Pharmacol*. 1991; 343(5): 472–477.
66. Räma P, Linnankoski I, Tanila H, Pertovaara A, Carlson S. Medetomidine, atipamezole, and guanfacine in delayed response performance of aged monkeys. *Pharmacol Biochem Behav*. 1996; 55(3): 415–422.
67. Kobori N, Clifton GL, Dash PK. Enhanced catecholamine synthesis in the prefrontal cortex after traumatic brain injury: implications for prefrontal dysfunction. *J Neurotrauma*. 2006; 23(7): 1094–1102.
68. Kobori N, Hu B, Dash PK. Altered adrenergic receptor signaling following traumatic brain injury contributes to working memory dysfunction. *Neuroscience*. 2011; 172: 293–302.
69. Kobori N, Moore AN, Dash PK. Altered regulation of protein kinase a activity in the medial prefrontal cortex of normal and brain-injured animals actively engaged in a working memory task. *J Neurotrauma*. 2015; 32(2): 139–148.
70. Barsegyan A, Mackenzie SM, Kurose BD, McGaugh JL, Ro ozonea B. Glucocorticoids in the prefrontal cortex enhance memory consolidation and impair working memory by a common neural mechanism. *Proc Natl Acad Sci U S A*. 2010; 107(38): 16655–16660.
71. Gründemann D, Schechinger B, Rappold GA, Schölig E. Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. *Nat Neurosci*. 1998; 1(5): 349–351.
72. Ro ozonea B, Nguyen BT, Power AE, McGaugh JL. Basolateral amygdala noradrenergic influence enhances enhancement of memory consolidation induced by hippocampal glucocorticoid receptor activation. *Proc Natl Acad Sci U S A*. 1999; 96(20): 11642–11647.
73. Qin S, Cousijn H, Rijpkema M, et al. The effect of moderate acute psychological stress on working memory-related neural activity is modulated by a genetic variation in catecholaminergic function in humans. *Front Integr Neurosci*. 2012; 6: 16.
74. Radley JJ, Rocher AB, Janssen WGM, Hof PR, McEwen BS, Morrison JH. Reversibility of apical dendritic retraction in the rat medial prefrontal cortex following repeated stress. *Exp Neurol*. 2005; 196(1): 199–203.
75. Radley JJ, Rocher AB, Miller M, et al. Repeated stress induces dendritic spine loss in the rat medial prefrontal cortex. *Cereb Cortex*. 2006; 16(3): 313–320.
76. Liston C, Miller MM, Goldwater DS, et al. Stress-induced alterations in prefrontal cortical dendritic morphology predict selective impairments in perceptual attentional set-shifting. *J Neurosci*. 2006; 26(30): 7870–7874.
77. Moda-Sava RN, Murdock MH, Parekh PK, et al. Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. *Science* 2019; 364: eaat8078.
78. Vyas A, Mitra R, Shankaranarayana Rao BS, Chattarji S. Chronic stress induces contrasting patterns of dendritic remodeling in hippocampal and amygdaloid neurons. *J Neurosci Off J Soc Neurosci*. 2002; 22(15): 6810–6818.
79. Shanks RM, Glavis-Bloom C, Lerman D, et al. Estrogen mediates sex differences in stress-induced prefrontal cortex dysfunction. *Mol Psychiatry*. 2004; 9(5): 531–538.
80. Shansky RM, Hamo C, Hof PR, Lou W, McEwen BS, Morrison JH. Estrogen promotes stress sensitivity in a prefrontal cortex-amygdala pathway. *Cereb Cortex*. 2010; 20(11): 2560–2567.

81. Hains AB, Yabe Y, Arnsten AFT. Chronic stimulation of alpha-2A-Adrenoceptors with guanfacine protects rodent prefrontal cortex dendritic spines and cognition from the effects of chronic stress. *Neurobiol Stress*. 2015; 2: 1–9.

82. Krystal JH, Abdallah CG, Averill LA, et al. Synaptic loss and the pathophysiology of PTSD: implications for keta-
mine as a prototype novel therapeutic. *Curr Psychiatry Rep.* 2017; 19(10): 74.

83. Bloss EB, Janssen WG, Ohm DT, et al. Evidence for reduced experience-dependent dendritic spine plasticity in the aging prefrontal cortex. *J Neurosci*. 2011; 31(21): 7831–7839.

84. Miner LH, Jedema HP, Moore FW, Blakely RD, Grace AA, Sesack SR. Chronic stress increases the plasmalemmal distribution of the norepinephrine transporter and the coexpression of tyrosine hydroxylase in norepinephrine axons in the prefrontal cortex. *J Neurosci*. 2006; 26 (5): 1571–1578.

85. Heyes MP, Lackner A. Increased cerebrospinal fluid quinolnolinic acid, kynurenic acid, and L-kynurenine in acute septicemia. *J Neurochem*. 1990; 55(1): 338–341.

86. Nold V, Sweatman C, Karabatsiak A, et al. Activation of the kynurenine pathway and mitochondrial respiration to face allostatic load in a double-hit model of stress. *Psychoneuroendocrinology*. 2019; 107: 148–159.

87. Schwarcz R. Kynurenines and glutamate: multiple links and therapeutic implications. *Adv Pharmacol*. 2016; 76: 13–37.

88. Schwarcz R, Stone TW. The kynurenine pathway and the brain: challenges, controversies and promises. *Neuropsychopharmacology*. 2017; 112(Pt B): 237–255.

89. Vornov JJ, Hollinger KR, Jackson PF, et al. Still of the kynurenine pathway and mitochondrial respiration and the pathophysiology of PTSD: implications for ketamine as a prototype novel therapeutic. *Curr Psychiatry Rep.* 2017; 19(10): 74.

90. Bloom EB, Janssen WG, Ohm DT, et al. Evidence for reduced experience-dependent dendritic spine plasticity in the aging prefrontal cortex. *J Neurosci*. 2011; 31(21): 7831–7839.

91. Conner JM, Lauterborn JC, Yan Q, Gall CM, Varon S. Distribution of Brain-Derived Neurotrophic Factor (BDNF) Protein and mRNA in the Normal Adult Rat CNS: Evidence for Anterograde Axonal Transport. *J Neurosci*. 1997; 17(7): 2295–2313.

92. Ernfors P, Wetmore C, Olson L, Persson H. Identification of cells in rat brain and peripheral tissues expressing mRNA for members of the nerve growth factor family. *Neuron*. 1990; 5(4): 511–526.

93. Hofer M, Paglusi SR, Hohn A, Leibrock J, Barde YA. Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain. *EMBO J*. 1990; 9(8): 2459–2464.

94. Pruunsild P, Kazantseva A, Aid T, Palm K, Timmusk T. Dissecting the human BDNF locus: Bidirectional transcrip-
tion, complex splicing, and multiple promoters. *Genomics*. 2007; 90(3): 397–406.

95. Mowla SJ, Farhari HF, Pareek S, et al. Biosynthesis and post-translational processing of the precursor to brain-
derived neurotrophic factor. *J Biol Chem*. 2001; 276(16): 12660–12666.

96. Lessmann V, Brigadski T. Mechanisms, locations, and kinetics of synaptic BDNF secretion: an update. *Neurosci Res*. 2009; 65(1): 11–22.

97. Yang B, Ren Q, Zhang J, Chen Q-X, Hashimoto K. Altered expression of BDNF, BDNF pro-peptide and their precursor proBDNF in brain and liver tissues from psychiatric disorders: rethinking the brain–liver axis. *Transl Psychiatry*. 2017; 7(5): e1128–e1128.

98. Zhang W, Wang T, Wang G, Yang M, Zhou Y, Yuan Y. Effects of Dexamethasone on Postoperative Delirium and Expression of IL-1β, IL-6, and TNF-α in Elderly Patients After Hip Fracture Operation. *Front Pharmacol*. 2020; 11: 678.

99. Deinhardt K, Chao MV. Shaping neurons: long and short range effects of mature and proBDNF signalling upon neu-
ronal structure. *Neuropsychopharmacology*. 2014; 76: 603–609.

100. Foltran RB, Diaz SL. BDNF isoforms: a round trip ticket expressing mRNA for members of the nerve growth factor in the prefrontal cortex. *Adv Pharmacol*. 2016; 76: 13–37.

101. Ota KT, Liu R-J, Voleti B, et al. REDD1 is essential for stress-induced synaptic loss and depressive behavior. *Nat Med*. 2014; 20(5): 531–535.

102. Kowiatński P, Lietzau G, Czuba E, Waśkow M, Steliga A, Moryś J. BDNF: A Key Factor with Multipotent Impact on Brain Signaling and Synaptic Plasticity. *Cell Mol Neurobiol*. 2018; 38(3): 579–593.

103. Lu B. BDNF and activity-dependent synaptic modulation. *Learn Mem*. 2003; 10(2): 86–98.

104. Miranda M, Morici JF, Zanoni MB, Bekinschtein P. Brain-Derived Neurotrophic Factor: A Key Molecule for Memory in the Healthy and the Pathological Brain. *Front Cell Neurosci*. 2019; 13: 363.

105. Pruunsild P, Kazantseva A, Aid T, Palm K, Timmusk T. Dissecting the human BDNF locus: Bidirectional transcrip-
tion, complex splicing, and multiple promoters. *Genomics*. 2007; 90(3): 397–406.

106. Mowla SJ, Farhari HF, Pareek S, et al. Biosynthesis and post-translational processing of the precursor to brain-
derived neurotrophic factor. *J Biol Chem*. 2001; 276(16): 12660–12666.

107. Lessmann V, Brigadski T. Mechanisms, locations, and kinetics of synaptic BDNF secretion: an update. *Neurosci Res*. 2009; 65(1): 11–22.

108. Yang B, Ren Q, Zhang J, Chen Q-X, Hashimoto K. Altered expression of BDNF, BDNF pro-peptide and their precursor proBDNF in brain and liver tissues from psychiatric disorders: rethinking the brain–liver axis. *Transl Psychiatry*. 2017; 7(5): e1128–e1128.

109. Zhang W, Wang T, Wang G, Yang M, Zhou Y, Yuan Y. Effects of Dexamethasone on Postoperative Delirium and Expression of IL-1β, IL-6, and TNF-α in Elderly Patients After Hip Fracture Operation. *Front Pharmacol*. 2020; 11: 678.

110. Deinhardt K, Chao MV. Shaping neurons: long and short range effects of mature and proBDNF signalling upon neu-
ronal structure. *Neuropsychopharmacology*. 2014; 76: 603–609.

111. Ota KT, Liu R-J, Voleti B, et al. REDD1 is essential for stress-induced synaptic loss and depressive behavior. *Nat Med*. 2014; 20(5): 531–535.

112. Kowiatński P, Lietzau G, Czuba E, Waśkow M, Steliga A, Moryś J. BDNF: A Key Factor with Multipotent Impact on Brain Signaling and Synaptic Plasticity. *Cell Mol Neurobiol*. 2018; 38(3): 579–593.

113. Lu B. BDNF and activity-dependent synaptic modulation. *Learn Mem*. 2003; 10(2): 86–98.

114. Miranda M, Morici JF, Zanoni MB, Bekinschtein P. Brain-Derived Neurotrophic Factor: A Key Molecule for Memory in the Healthy and the Pathological Brain. *Front Cell Neurosci*. 2019; 13: 363.
112. Lu B, Pang PT, Woo NH. The yin and yang of neurotrophin action. *Nat Rev Neurosci*. 2005; 6(8): 603–614.

113. Pozzo-Miller LD, Gottschalk W, Zhang L, et al. Impairments in high-frequency transmission, synaptic vesicle docking, and synaptic protein distribution in the hippocampus of BDNF knockout mice. *J Neurosci*. 1999; 19(12): 4972–4983.

114. Rosch H, Schweigreiter R, Bonhoeffer T, Barde Y-A, Korte M. The neurotrophin receptor p75NTR modulates long-term depression and regulates the expression of AMPA receptor subunits in the hippocampus. *Proc Natl Acad Sci USA*. 2005; 102(20): 7362–7367.

115. Sakata K, Martinowich K, Woo NH, et al. Role of activity-dependent BDNF expression in hippocampal-prefrontal cortical regulation of behavioral perseverance. *Proc Natl Acad Sci USA*. 2013; 110(37): 15103–15108.

116. Xu B, Gottschalk W, Chow A, et al. The role of brain-derived neurotrophic factor receptors in the mature hippocampus: modulation of long-term potentiation through a presynaptic mechanism involving TrkB. *J Neurosci*. 2000; 20(18): 6888–6897.

117. Yang J, Siao C-J, Nagappan G, et al. Neuronal release of proBDNF. *Nat Neurosci*. 2009; 12(2): 113–115.

118. Gottmann K, Mittmann T, Lessmann V. BDNF signaling in the formation, maturation and plasticity of glutamatergic and GABAergic synapses. *Exp Brain Res*. 2009; 199(3-4): 203–234.

119. Kumar V, Zhang M-X, Swank MW, Kunz J, Wu G-Y. Regulation of Dendritic Morphogenesis by Ras-P13K-Akt-mTOR and Ras-MAPK Signaling Pathways. *J Neurosci*. 2005; 25(49): 11288–11299.

120. McAllister AK, Katz LC, Lo DC. Neurotrophin regulation of cortical dendritic growth requires activity. *Neuron*. 1996; 17(6): 1057–1064.

121. McAllister AK, Lo DC, Katz LC. Neurotrophins regulate dendritic growth in developing visual cortex. *Neuron*. 1995; 15(4): 791–803.

122. McAllister AK, Katz LC, Lo DC. Neurotrophins and synaptic plasticity. *Annu Rev Neurosci*. 1999; 22: 295–318.

123. Zagrebelsky M, Korte M. Form follows function; BDNF and its involvement in sculpting the function and structure of synapses. *Neuropharmacology*. 2014; 76: 628–638.

124. Ji Y, Pang PT, Feng L, Lu B. Cyclic AMP controls BDNF-induced TrkB phosphorylation and dendritic spine formation in mature hippocampal neurons. *Nat Neurosci*. 2005; 8(2): 164–172.

125. Kwon H-B, Sabatini BL. Glutamate induces de novo growth of functional spines in developing cortex. *Nature*. 2011; 474(7349): 100–104.

126. Shimada A, Mason CA, Morrison ME. TrkB signaling modulates spine density and morphology independent of dendrite structure in cultured neonatal Purkinje cells. *J Neurosci*. 1998; 18(21): 8559–8570.

127. Tyler WJ, Pozzo-Miller L. Miniature synaptic transmission and BDNF modulate dendritic spine growth and form in rat CA1 neurons. *J Physiol*. 2003; 553(Pt 2): 497–509.

128. Tyler WJ, Pozzo-Miller LD. BDNF enhances quantal neurotransmitter release and increases the number of docked vesicles at the active zones of hippocampal excitatory synapses. *J Neurosci*. 2001; 21(12): 4249–4258.

129. Ji Y, Lu Y, Yang F, et al. Acute and gradual increases in BDNF concentration elicit distinct signaling and functions in neurons. *Nat Neurosci*. 2010; 13(3): 302–309.

130. Kellner Y, GaDecke N, Dierkes T, Thieme N, Zagrebelsky M, Korte M. The BDNF effects on dendritic spines of mature hippocampal neurons depend on neuronal activity. *Front Synaptic Neurosci*. 2014; 6:5.

131. Ernfors P, Lee K-F, Jaenisch R. Mice lacking brain-derived neurotrophic factor develop with sensory deficits. *Nature*. 1994; 368(6467): 147–150.

132. Harward SC, Hedrick NG, Hall CE, et al. Autocrine BDNF-TrkB signalling within a single dendritic spine. *Neuron*. 2016; 538(7623): 99–103.

133. Parpura V, Zorec R. Gliotransmission: exocytotic release from astrocytes. *Brain Res Rev*. 2010; 63(1-2): 83–92.

134. Parkhurst CN, Yang G, Ninan I, et al. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. *Cell*. 2013; 155(7): 1596–1609.

135. Gomes C, Ferreira R, George J, et al. Activation of microglial cells triggers a release of brain-derived neurotrophic factor (BDNF) inducing their proliferation in an adenosine A2A receptor-dependent manner: A2A receptor blockade prevents BDNF release and proliferation of microglia. *J Neuroinflammation*. 2013; 10(1): 780.

136. Song M, Martinowich K, Lee FS. BDNF at the synapse: why location matters. *Mol Psychiatry*. 2017; 22(10): 1370–1375.

137. Ernfors P, Bengzon J, Kokaia Z, Persson H, Lindvall O. Increased levels of messenger RNAs for neurotrophic factors in the brain during kindling epileptogenesis. *Neuron*. 1991; 7(1): 165–176.

138. Castrén E, Zafra F, Thoenen H, Lindholm D. Light regulates expression of brain-derived neurotrophic factor mRNA in rat visual cortex. *Proc Natl Acad Sci U S A*. 1992; 89(20): 9444–9448.

139. Palomer E, Carretero J, Benvegnu S, Dotti CG, Martin MG. Neuronal activity controls Bdnf expression via Polycomb de-repression and CREB/CBP/JMJD3 activation in mature neurons. *Nat Commun*. 2016; 7: 11081.

140. Patterson SL, Grover LM, Schwartzkroin PA, Bothwell M. Neurotrophin expression in rat hippocampal slices: A stimulus paradigm inducing LTP in CA1 evokes increases in BDNF and NT-3 mRNAs. *Neuron*. 1992; 9(6): 1081–1088.

141. Gómez-Pinilla F, So V, Kesslak JP. Spatial learning induces neurotrophin receptor and synapsin I in the hippocampus. *Brain Res*. 2001; 904(1): 13–19.

142. Hall J, Thomas KL, Everitt BJ. Rapid and selective induction of BDNF expression in the hippocampus during contextual learning. *Nat Neurosci*. 2000; 3(6): 533–535.

143. Silhol M, Arancibia S, Maurice T, Tapia-Arancibia L. Spatial memory training modifies the expression of brain-derived neurotrophic factor tyrosine kinase
receptors in young and aged rats. *Neuroscience*. 2007; 146 (3): 962–973.

144. Tokuyama W, Okuno H, Hashimoto T, Xin Li Y, Miyashita Y. BDNF upregulation during declarative memory formation in monkey inferior temporal cortex. *Nat Neurosci*. 2000; 3(11): 1134–1142.

145. Tao X, Finkbeiner S, Arnold DB, Shaywitz AJ, Greenberg ME. Ca2+ Influx Regulates BDNF Transcription by a CREB Family Transcription Factor-Dependent Mechanism. *Neuron*. 1998; 20(4): 709–726.

146. Zafra F, Castrén E, Thoenen H, Lindholm D. Interplay between glutamate and gamma-aminobutyric acid transmission systems in the physiological regulation of brain-derived neurotrophic factor and nerve growth factor synthesis in hippocampal neurons. *Proc Natl Acad Sci U S A*. 1991; 88(22): 10037–10041.

147. Zafra F, Hengerer B, Lebrock J, Thoenen H, Lindholm D. Activity-dependent regulation of BDNF and NGF mRNAs in the rat hippocampus is mediated by non-NMDA glutamate receptors. *EMBO J*. 1990; 9(11): 3545–3550.

148. Zafra F, Lindholm D, Castrén E, Hartikka J, Thoenen H. Regulation of brain-derived neurotrophic factor and nerve growth factor mRNA in primary cultures of hippocampal neurons and astrocytes. *J Neurosci*. 1992; 12(12): 4793–4799.

149. Anastasia A, Deinhardt K, Chao MV, et al. Val66Met polymorphism of BDNF alters prodomain structure to induce neuronal growth cone retraction. *Nat Commun*. 2013; 4: 2490.

150. Balkowiec A, Katz DM. Activity-dependent release of endogenous brain-derived neurotrophic factor from primary sensory neurons detected by ELISA in situ. *J Neurosci*. 2000; 20(19): 7417–7423.

151. Gartner A, Staiger V. Neurotrophin secretion from hippocampal neurons evoked by long-term-potentiation-induced electrical stimulation patterns. *Proc Natl Acad Sci U S A*. 2002; 99(9): 6386–6391.

152. Lever JI, Bradbury EJ, Cunningham JR, et al. Brain-derived neurotrophic factor is released in the dorsal horn by distinctive patterns of afferent fiber stimulation. *J Neurosci*. 2001; 21(12): 4469–4477.

153. Bath KG, Schilit A, Lee FS. Stress effects on BDNF expression: effects of age, sex, and form of stress. *Neuroscience*. 2013; 239: 149–156.

154. Bennett MR, Lagopoulos J. Stress and trauma: BDNF control of dendritic-spine formation and regression. *Prog Neurobiol*. 2014; 112: 80–92.

155. Murinová J, Hlavičková N, Chmelová M, Riečanský I. The Evidence for Altered BDNF Expression in the Brain of Rats Reared or Housed in Social Isolation: A Systematic Review. *Front Behav Neurosci*. 2017; 11: 101.

156. Murakami S, Imbe H, Morikawa Y, Kubo C, Senba E. Chronic stress, as well as acute stress, reduces BDNF mRNA expression in the rat hippocampus but less robustly. *Neurosci Res*. 2005; 53(2): 129–139.

157. Lakshminarasimhan H, Chattarji S. Stress leads to contrasting effects on the levels of brain derived neurotrophic factor in the hippocampus and amygdala. *PLoS One*. 2012; 7(1):e30481.

158. Guo J, Ji Y, Ding Y, et al. BDNF pro-peptide regulates dendritic spines via caspase-3. *Cell Death Dis*. 2016; 7: e2264–e2264.

159. Jain V, Baitharu I, Prasad D, Iluvazhagan G. Enriched Environment Prevents Hypobaric Hypoxia Induced Memory Impairment and Neurodegeneration: Role of BDNF/Pi3K/GSK3β Pathway Coupled with CREB Activation. *PLoS One*. 2013; 8(5): e62235.

160. Hoefler CA, Klann E. mTOR signaling: at the crossroads of plasticity, memory and disease. *Trends Neurosci*. 2010; 33(2): 67–75.

161. Kang H, Schuman EM. A requirement for local protein synthesis in neurotrophin-induced hippocampal synaptic plasticity. *Science*. 1996; 273(5280): 1402–1406.

162. Takei N, Kawamura M, Hara K, Yonezawa K, Nawa H. Brain-Derived Neurotrophic Factor Induces Mammalian Target of Rapamycin-Dependent Local Activation of Translation Machinery and Protein Synthesis in Neuronal Dendrites. *J Neurosci*. 2004; 24(44): 9760–9769.

163. Tang SJ, Reis G, Kang H, Gingras A-C, Sonenberg N, Schuman EM. A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. *Proc Natl Acad Sci U S A*. 2002; 99(1): 467–472.

164. Buffington SA, Huang W, Costa-Mattioli M. Translational control in synaptic plasticity and cognitive dysfunction. *Annu Rev Neurosci*. 2014; 37: 17–38.

165. Takei N, Kawamura M, Hara K, Yonezawa K, Nawa H. Brain-derived Neurotrophic Factor Enhances Neuronal Translation by Activating Multiple Initiation Processes: COMPARISON WITH THE EFFECTS OF INSULIN. *J Biol Chem*. 2001; 276(46): 42818–42825.

166. Hare BD, Ghosal S, Duman RS. Rapid acting antidepressants in chronic stress models: molecular and cellular mechanisms. *Chronic Stress*. 2017; 1: 247054701769731.

167. Hare BD, Shinohara R, Liu RJ, Pothula S, DiLeone RJ, Duman RS. Optogenetic stimulation of medial prefrontal cortex Drd1 neurons produces rapid and long-lasting antidepressant effects. *Nat Commun*. 2019; 10(1): 223.

168. Altar CA. Neurotrophins and depression. *Trends Pharmacol Sci*. 1999; 20(2): 59–62.

169. Duman RS, Deyama S, Fogac¸a MV. Role of BDNF in the pathophysiology and treatment of depression: activity-dependent effects distinguish rapid-acting antidepressants. *Eur J Neurosci*. 2021; 53(1): 126–139.

170. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. *Biol Psychiatry*. 2006; 59(12): 1116–1127.

171. Duman RS, Aghajanian GK, Sanacora G, et al. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. *Nat Med*. 2016; 22(3): 238–249.

172. Karege F, Vaudan G, Schwald M, Perroud N, La Harpe R. Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. *Mol Brain Res*. 2005; 136(1-2): 29–37.
173. Oh H, Piantadosi SC, Rocco BR, Lewis DA, Watkins SC, Sibille E. The Role of Dendritic Brain-Derived Neurotrophic Factor Transcripts on Altered Inhibitory Circuitry in Depression. *Biol Psychiatry*. 2019; 85(6): 517–526.

174. Björkholm C, Monteggia LM. BDNF – a key transducer of antidepressant effects. *Neuropsychopharmacology*. 2016; 102: 72–79.

175. Buchman AS, Yu L, Boyle PA, Schneider JA, De Jager PL, Bennett DA. Higher brain BDNF gene expression is associated with slower cognitive decline in older adults. *Neurology*. 2016; 86(8): 735–741.

176. Koleske AJ. Molecular mechanisms of dendrite stability. *Nat Rev Neurosci*. 2013; 14(8): 536–550.

177. Birnbaum SG, Yuan PX, Wang M, et al. Protein kinase C overactivity impairs prefrontal cortical regulation of working memory. *Science*. 2004; 306(5697): 882–884.

178. Larsson C. Protein kinase C and the regulation of the actin cytoskeleton. *Cell Signal*. 2006; 18(3): 276–284.

179. Graber S, Maiti S, Halpain S. Cathepsin B-like proteolysis of MARCKS in maintaining dendritic spine morphology. *Neuron*. 2005; 48(1): 77–90.

180. Graber S, Maiti S, Halpain S. Cathepsin B-like proteolysis and MARCKS degradation in sub-lethal NMDA-induced collapse of dendritic spines. *Neuropsychopharmacology*. 2004; 47(5): 706–713.

181. Bennett V, Gardner K, Steiner JP. Brain adducin: a protein kinase C substrate for protein kinase C substrate that may mediate site-directed assembly at the spectrin-actin junction. *J Biol Chem*. 1988; 263(12): 5860–5869.

182. Konopaske GT, Lange N, Coyle JT, Benes FM. Altered expression of CDC42 signaling pathway components in cortical layer 3 pyramidal cells in schizophrenia. *Am J Psychiatry*. 2017; 174(2): 163–171.

183. Autry AE, Monteggia LM. Brain-Derived neurotrophic factor and neuropsychiatric disorders. *Pharmacol Rev*. 2012; 64(2): 238–258.

184. Konopaske GT, Lange N, Coyle JT, Benes FM. Altered expression of CDC42 signaling pathway components in cortical layer 3 pyramidal cells in schizophrenia. *Biochem Pharmacol*. 2015; 78(11): 775–785.

185. Datta D, Arion D, Roman KM, Volk DW, Lewis DA. Altered expression of ARP2/3 complex signaling pathway genes in prefrontal layer 3 pyramidal cells in schizophrenia. *Am J Psychiatry*. 2017; 174(2): 163–171.

186. Hill JJ, Hashimoto T, Lewis DA. Molecular mechanisms contributing to dendritic spine alterations in the prefrontal cortex of subjects with schizophrenia. *Mol Psychiatry*. 2006; 11(6): 557–566.

187. Datta D, Arion D, Roman KM, Volk DW, Lewis DA. Altered cortical CDC42 signaling pathways in schizophrenia: implications for dendritic spine deficits. *Biol Psychiatry*. 2010; 68(1): 25–32.

188. Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. *Arch Gen Psychiatry*. 2000; 57(1): 65–73.

189. Konopaske GT, Lange N, Coyle JT, Benes FM. Prefrontal cortical dendritic spine pathology in schizophrenia and bipolar disorder. *JAMA Psychiatry*. 2014; 71(12): 1323–1331.

190. Arnsten AFT, Wang MJ, Paspalas CD. Neurmodulation of thought: flexibilities and vulnerabilities in prefrontal cortical network synapses. *Neuron*. 2012; 76(1): 223–239.

191. Brennan AR, Dolinsky B, Vu M-AT, Stanley M, Yeckel MF, Arnsten AFT. Blockade of IP3-mediated SK channel signaling in the rat medial prefrontal cortex improves spatial working memory. *Learn Mem Cold Mem*. 2008; 15(3): 93–96.

192. Chakroborty S, Guvassakov I, Miller MB, Stuttmann GE. Deviant ryanodine receptor-mediated calcium release resets synaptic homeostasis in presymptomatic 3xTg-AD mice. *J Neurosci*. 2009; 29(30): 9458–9470.

193. Cheung K-H, Shineman D, Müller M, et al. Mechanism of Ca2+ disruption in Alzheimer’s disease by presenilin regulation of InsP3 receptor channel gating. *Neuron*. 2008; 58(6): 871–883.

194. Foster TC. Calcium homeostasis and modulation of synaptic plasticity in the aged brain. *Aging Cell*. 2007; 6(3): 319–325.
204. Lacampagne A, Liu X, Reiken S, et al. Post-translational remodeling of Ryanodine receptor induces calcium leak leading to Alzheimer’s disease-like pathologies and cognitive deficits. Acta Neuropathol. 2017; 134(5): 749–767.

205. Stutzmann GE, Smith I, Caccamo A, Oddo S, Laferla FM, Parker I. Enhanced Ryanodine receptor contribution to Ca2+ disruptions in young, adult, and aged Alzheimer’s disease mice. J Neurosci. 2006; 26(19): 5180–5189.

206. Youle RJ, van der Bliek AM. Mitochondrial fission, fusion, and stress. Science. 2012; 337(6098): 1062–1065.

207. Contreras L, Drago I, Zampese E, Pozzan T. Mitochondria: The calcium connection. Biochim Biophys Acta. 2010; 1797(6-7): 607–618.

208. Wang X, Schwarz TL. The mechanism of Ca2+ mobilization from stores, but not by activation of Store-operated Ca2+ channels. J Physiol. 2006; 529 Pt 1: 57–68.

209. Giacomello M, Drago I, Bortolozzi M, et al. Ca2+ concentrations in the nucleus: spiking and the nuclear envelope. J Neurosci. 2007; 27(20): 5502–5507.

210. Filadi R, Greotti E, Turacchio G, Luini A, Pozzan T, Pizzo P. Mitofusin 2 ablation increases endoplasmic reticulum-mitochondria coupling. Proc Natl Acad Sci U S A. 2015; 112(17): E2174–2181.

211. Giorgi C, Missiroli S, Patergnani S, Duszynski J, Adam-Vizi V, Starkov AA. Calcium and mitochondrial dynamics: implications for energy production. Biochim Biophys Acta. 2015; 1852(12): 2388–2397.

212. Manczak M, Calkins MJ, Reddy PH. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer’s disease: implications for neuronal damage. Hum Mol Genet. 2011; 20(13): 2495–2509.

213. Rossi MJ, Pekkurnaz G. Powerhouse of the mind: mitochondrial plasticity at the synapse. Curr Opin Neurol. 2019; 32(1): 149–155.

214. Vaillant-Beuchot L, Mary A, Pardossi-Piquard R, et al. Accumulation of amyloid precursor protein C-terminal fragments triggers mitochondrial structure, function, and mitophagy defects in Alzheimer’s disease models and human brains. Acta Neuropathol. 2021; 141(1): 39–65.

215. Morozov YM, Datta D, Paspalas CD, Arnsten AF. Ultrastructural evidence for impaired mitochondrial fission in the aged rhesus monkey dorsolateral prefrontal cortex. Neurobiol Aging. 2017; 51: 9–18.

216. Tyumentseva MA, Stefanova NA, Kiseleva EV, Kolosova NG. Mitochondria with Morphology Characteristic for Alzheimer’s Disease Patients Are Found in the Brain of OXYS Rats. Biochem (Mosc). 2018; 83(9): 1083–1088.

217. Varró G, Romanello V, Varanita T, et al. DRP1-mediated mitochondrial shape controls calcium homeostasis and muscle mass. Nat Commun. 2019; 10(1): 2576.

218. Gomes LC, Di Benedetto G, Scorrano L. During autophagy mitochondria elongate, are spared from degradation and sustain cell viability. Nat Cell Biol. 2011; 13(5): 589–598.

219. Westermann B. Bioenergetic role of mitochondrial fusion and fission. Biochim Biophys Acta. 2012; 1817(10): 1833–1838.

220. Camellos-Almaraz MC, Pozo MJ, Murphy MP, Camellos PJ. Mitochondrial production of oxidants is necessary for physiological calcium oscillations. J Cell Physiol. 2006; 206(2): 487–494.

221. Park S, Won J-H, Hwang I, Hong S, Lee HK, Yu J-W. Defective mitochondrial fission augments NLRP3 inflammasome activation. Sci Rep. 2015; 5: 15489.

222. Park S, Won J-H, Hwang I, Hong S, Lee HK, Yu J-W. Defective mitochondrial fission augments NLRP3 inflammasome activation. Sci Rep. 2015; 5: 15489.

223. Adam-Vizi V, Starkov AA. Calcium and mitochondrial reactive oxygen species generation: how to read the facts. J Alzheimers Dis. 2010; 20 Suppl 2:S413–426.

224. Hereculano-Houzel S, Mota B, Lent R. Cellular scaling rules for rodent brains. Proc Natl Acad Sci U S A. 2006; 103(32): 12138–12143.

225. Hereculano-Houzel S, Collins CE, Wong P, Kaas JH. Cellular scaling rules for primate brains. Proc Natl Acad Sci U S A. 2007; 104(9): 3562–3567.

226. Hereculano-Houzel S. The human brain in numbers: a linearly scaled-up primate brain. Front Hum Neurosci. 2009; 3: 31.

227. Lee J-H, Kim J, Noh S, et al. Astrocytes phagocyte adult hippocampal synapses for circuit homeostasis. Nature. 2020; 590(7847): 612–617.
239. Chung W-S, Barres BA. The role of glial cells in synapse elimination. *Curr Opin Neurobiol*. 2012; 22(3): 438–445.

240. Chung W-S, Welsh CA, Barres BA, Stevens B. Do glia drive synaptic and cognitive impairment in disease? *Nat Neurosci*. 2015; 18(11): 1539–1545.

241. Darabid H, Arbour D, Robitaille R. Glial cells decipher synaptic competition at the mammalian neuromuscular junction. *J Neurosci*. 2013; 33(4): 1297–1313.

242. Fuentes-Medel Y, Logan MA, Ashley J, Ataman B, Budnik V, Freeman MR. Glia and Muscle Sculpt Neuromuscular Arbors by Engulfing Destabilized Synaptic Boutons and Shed Presynaptic Debris. *PLoS Biol*. 2009; 7(8): e1000184.

243. Lee E, Chung W-S. Glial control of synapse number in healthy and diseased brain. *Front Cell Neurosci*. 2019; 13(42).

244. Mallat M, Marín-Teva JL, Chéret C. Phagocytosis in the developing CNS: more than clearing the corpses. *Curr Opin Neurobiol*. 2005; 15(1): 101–107.

245. Roche SL, Sherman DL, Dissanayake K, et al. Loss of glial Neurofascin155 delays developmental synapse elimination at the neuromuscular junction. *J Neurosci*. 2014; 34(38): 12904–12918.

246. Hong S, Beja-Glasser VF, Nfonomiy BM, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. *Science*. 2016; 352(6286): 712–716.

247. Hong S, Dissing-Olesen L, Stevens B. New insights on the role of microglia in synaptic pruning in health and disease. *Curr Opin Neurobiol*. 2016; 36: 128–134.

248. Liddelow SA, Marsh SE, Stevens B. Microglia and astrocytes in disease: dynamic duo or partners in crime? *Trends Immunol*. 2020; 41(9): 820–835.

249. Rajendran L, Paolicelli RC. Microglia-Mediated synapse loss in Alzheimer’s disease. *J Neurosci*. 2018; 38(12): 2911–2919.

250. Stephan AH, Barres BA, Stevens B. The complement system: an unexpected role in synaptic pruning during development and disease. *Annu Rev Neurosci*. 2012; 35: 369–389.

251. Scott-Hewitt N, Perrucci F, Morini R, et al. Local externalization of phosphatidylserine mediates developmental synaptic pruning by microglia. *EMBO J*. 2020; 39(16): e105380.

252. Sapar ML, Ji H, Wang B, et al. Phosphatidylserine externalization results from and causes neurite degeneration in drosophila. *Cell Rep*. 2018; 24(9): 2273–2286.

253. Kuo CT, Zhu S, Younger S, Jan LY, Jan YN. Identification of E2/E3 ubiquitinating enzymes and caspase activity regulating Drosophila sensory neuron dendrite pruning. *Neuron*. 2006; 51(3): 283–290.

254. Erturk A, Wang Y, Sheng M. Local pruning of dendrites and spines by caspase-3-dependent and proteasome-limited mechanisms. *J Neurosci*. 2014; 34(5): 1672–1688.

255. Vilalta A, Brown GC. Neurophagy, the phagocytosis of live neurons and synapses by glia, contributes to brain development and disease. *FEBS J*. 2018; 285(19): 3566–3575.

256. Chung W-S, Clarke LE, Wang GX, et al. Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. *Nature*. 2013; 504(7480): 394–400.

257. Dzamko N, Geczy CL, Halliday GM. Inflammation is genetically implicated in Parkinson’s disease. *Neuroscience*. 2015; 302: 89–102.

258. Gandhi S, Wood NW. Genome-wide association studies: the key to unlocking neurodegeneration? *Nat Neurosci*. 2010; 13(7): 789–794.

259. Hammond TR, Marsh SE, Stevens B. Immune signaling in neurodegeneration. *Immunity*. 2019; 50(4): 955–974.

260. Sekar A, Bialas AR, de Rivera H, Schizophrenia Working Group of the Psychiatric Genomics Consortium, et al. Schizophrenia risk from complex variation of complement component 4. *Nature*. 2016; 530(7589): 177–183.

261. Woo JJ, Pouget JG, Zai CC, Kennedy JL. The complement system in schizophrenia: where are we now and what’s next? *Mol Psychiatry*. 2020; 25(1): 114–130.

262. Carrasquillo MM, Crook JE, Pedraza O, et al. Late-onset Alzheimer’s risk variants in memory decline, incident mild cognitive impairment, and Alzheimer’s disease. *Neurobiol Aging*. 2015; 36(1): 60–67.

263. Crehan H, Holton P, Wray S, Pocock J, Guerreiro R, Hardy J. Complement receptor 1 (CR1) and Alzheimer’s disease. *Immunobiology*. 2012; 217(2): 244–250.

264. Elias-Sonnenschein LS, Helisalmi S, Natunen T, et al. Genetic loci associated with Alzheimer’s disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort. *PLoS One*. 2013; 8(4): e59676.

265. Lambert JC, Ibrahim-Verbaas CA, Harold D, European Alzheimer’s Disease Initiative (EADI), et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. *Nat Genet*. 2013; 45(12): 1452–1458.

266. Presumej Y, Bialas AR, Carroll MC. Complement System in Neural Synapse Elimination in Development and Disease. In: Alt F (eds) *Advances in Immunology*. Amsterdam: Elsevier, 2017, pp. 53–79.

267. Gasque P, Singhrao SK, Neal JW, et al. The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis. *J Immunol*. 1950 1998; 160: 3543–3554.

268. Corriveau RA, Huh GS, Shatz CJ. Regulation of class I MHC gene expression in the developing and mature CNS by neural activity. *Neuron*. 1998; 21(3): 505–520.

269. Datwani A, McConnell MJ, Kanold PO, et al. Classical MHC class I H2-Db. *Cell Rep*. 2018; 24(9): 2273–2286.

270. Lee H, Brott BK, Kirkby LA, et al. Synapse elimination and learning rules co-regulated by MHC class I H2-Db. *Nature*. 2014; 509(7499): 195–200.

271. Wake H, Moorhouse AJ, Miyamoto A, Nabekura J. Microglia: actively surveying and shaping neuronal...
circuit structure and function. *Trends Neurosci.* 2013; 36(4): 209–217.

272. Stevens B, Allen NJ, Vazquez LE, et al. The classical complement cascade mediates CNS synapse elimination. *Cell.* 2007; 131(6): 1164–1178.

273. Bialas AR, Stevens B. TGF-β signaling regulates neuronal C1q expression and developmental synaptic refinement. *Nat Neurosci.* 2013; 16(12): 1773–1782.

274. Gaya da Costa M, Poppelaars F, van Kooten C, et al. Age and sex-associated changes of complement activity and complement levels in a healthy Caucasian population. *Front Immunol.* 2018; 9: 2664.

275. Schafer DP, Lehrman EK, Kautzman AG, et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. *Neuron.* 2012; 74(4): 691–705.

276. Stephan AH, Madison DV, Mateos JM, et al. A dramatic increase of C1q protein in the CNS during normal aging. *J Neurosci.* 2013; 33(33): 13460–13474.

277. Mathys H, Davila-Velderrain J, Peng Z, et al. Single-cell transcriptomic analysis of Alzheimer’s disease. *Nature.* 2019; 570(7761): 332–337.

278. Fonseca MI, Zhou J, Botto M, Tenner AJ. Absence of C1q Leads to Less Neuropathology in Transgenic Mouse Models of Alzheimer’s Disease. *J Neurosci.* 2004; 24(29): 6457–6465.

279. Fonseca MI, Kawas CH, Troncoso JC, Tenner AJ. Neuronal localization of C1q in preclinical Alzheimer’s disease. *Neurobiol Dis.* 2004; 15(1): 40–46.

280. Wyss-Coray T, Yan F, Lin AH-T, et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer’s mice. *Proc Natl Acad Sci U S A.* 2002; 99(16): 10837–10842.

281. Connor DF, Grasso DJ, Slivinsky MD, Pearson GS, Banga A. An open-label study of guanfacine extended release for traumatic stress related symptoms in children and adolescents. *J Child Adolesc Psychopharmacol.* 2013; 23(4): 244–251.

282. McAllister TW, McDonald BC, Flashman LA, et al. Alpha-2 adrenergic challenge with guanfacine one month after mild traumatic brain injury: altered working memory and BOLD response. *Int J Psychophysiol.* 2011; 82(1): 107–114.

283. Blumberg HP, Krystal JH, Bansal R, et al. Age, rapid-cycling, and pharmacotherapy effects on ventral prefrontal cortex in bipolar disorder: a cross-sectional study. *Biol Psychiatry.* 2006; 59(7): 611–618.

284. Licznerski P, Duman RS. Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression. *Neuroscience.* 2013; 251: 33–50.